Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's ...

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...